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An investigation of the essential oil (EO) and the crude MeOH extract of a Bhutanese variety of Ajania
nubigena using GC/GC-MS and NMR found the following: a) one kg of the dried plant material contained
0.7% w/w EO; b) 44 of the 53 GC-FID peaks of the EO were identified with (3R,6R)-linalool oxide acetate
(75.8 %) as the major constituent (chemotype II) and chamazulene as a new sub-chemotype; c) purification
of the EO furnished (3R,6R)-linalool oxide acetate (1), chamazulene (2),
(E)-2-(2,4-hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene (3), and
(Z)-2-(2,4-hexadinylidene)-1,6-dioxaspiro[4,4]non-3-ene (4); d) from the crude MeOH extract, four
flavonoid compounds: 1-(4-hydroxyphenyl)propan-1-one (5), oxyanin B (6), luteolin (7) (major) and the
luteolin-7-O-�- D-glucoside (8) were isolated; e) among the EO and pure compounds tested for biological
activities, compound 7 exhibited a broad range of moderate antiplasmodial, cytoxicity and antimicrobial
activities; c) compound 8 showed significant in vitro antiplasmodial activity against P. falciparum strains
TM4/8.2 and K1CB1 (multidrug resistant strain) and was identified as a potential antimalarial scaffold; and
f) the in vitro antimicrobial and cytotoxicity activities were in alignment with the traditional medical uses of
this plant and thus substantiate its use in Bhutanese traditional medicine.
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An investigation of the essential oil (EO) and the crude MeOH extract of a Bhutanese variety of Ajania nubigena using GC/GC-MS and NMR found the 
following: a) one kg of the dried plant material contained 0.7% w/w EO; b) 44 of the 53 GC-FID peaks of the EO were identified with (3R,6R)-linalool oxide 
acetate (75.8 %) as the  major constituent (chemotype II) and chamazulene as a new sub-chemotype; c) purification of the EO furnished (3R,6R)-linalool oxide 
acetate (1), chamazulene (2), (E)-2-(2,4-hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene (3), and (Z)-2-(2,4-hexadinylidene)-1,6-dioxaspiro[4,4]non-3-ene (4); 
d) from the crude MeOH extract, four flavonoid compounds: 1-(4-hydroxyphenyl)propan-1-one (5), oxyanin B (6), luteolin (7) (major) and the luteolin-7-O-β-
D-glucoside (8) were isolated; e) among the EO and pure compounds tested for biological activities, compound 7 exhibited a broad range of moderate 
antiplasmodial, cytoxicity and antimicrobial activities; c) compound 8 showed significant in vitro antiplasmodial activity against P. falciparum strains TM4/8.2 
and K1CB1 (multidrug resistant strain) and was identified as a potential antimalarial scaffold; and f) the in vitro antimicrobial and cytotoxicity activities were 
in alignment with the traditional medical uses of this plant and thus substantiate its use in Bhutanese traditional medicine. 
 




Ajania is a relatively small genus of the family Asteraceae with 
only 28-40 species which are found in Russia and Asia (Bhutan, 
Nepal, India, Tibet, China and Japan) [1-3]. In Bhutan, only two 
Ajania species: A. nubigena and A. myriantha have been reported 
[4]. A. nubigena is locally known as m.khan-d.kar and contributes 
to the preparation of at least four important multi-ingredient 
Essential Traditional Medicine Drugs (ETMDs) or polyherbal 
formulations [5] including a popular product called b.dud-rtsi nga-
lum (Five Herbal Ambrosia). ‘Five Herbal Ambrosia’ is used in spa 
related health care practices. As an individual plant, it is used in the 
Bhutanese traditional medicine (BTM) as incense, vulnerary, 
expectorant, styptic and anti-epistaxis and also for treating 
abscesses, swelling of limbs, tumor and kidney infections [6].  
 
A. nubigena has been ascribed different synonyms/basonyms as 
Artemisia nubigena, Dendranthema nubigenum, Chrysanthemum 
nubigenum and Tanacetum nubigenum [7]. Varieties of this plant 
growing in different regions of India, including Kumaon, Garwal, 
Uttarakhand and Uttar Pradesh, have been classified based on three 
main chemotypes of their essential oils (EO) [8-12]. Chemotype I 
contained bornyl acetate (39.7%) as a major marker constituent of 
the EO while chemotype II and III contained (3R,6R)-linalool oxide 
acetate (69.4%) and (-)-cis-chrysanthenol (37.0%) as their principal 
components, respectively [8].  
 
While the Indian varieties of A. nubigena (ascribed under the 
basonym Tanacetum nubigenum) have been studied [8-12], a 
Bhuatanese variety growing in the extreme vegetation and climatic 
conditions of the Bhutan Himalaya has not been investigated for its 
phytochemicals or biological activities, especially for antimalarial 
activity and cytotoxicity. Moreover, these studies on the Indian 
varieties of A. nubigena reported the analysis of the EO of the fresh 
plant material, which is contrary to the manner in which this plant is 
used by the local people in India, Nepal and Bhutan, who use it in 
its dried form. Differences in the quality and the chemical 
constituents of these differently prepared plant samples were thus 
expected. Therefore, in order to scientifically validate the Bhutanese 
ethnopharmacological uses of this plant in its authentic manner of 
usage, we initially studied the antimalarial, antimicrobial and 
cytotoxicity activities of various crude solvent extracts of this dried 
plant material [6]. These preliminary studies indicated that the plant 
was a good source of antimalarial and antimicrobial agents. This 
encouraged us to investigate the chemical components of the EO 
and the methanol extract of the dried plant material. The EO and the 
isolated major phytochemicals were assessed for their antimalarial, 
antimicrobial and cytotoxic activities and the results are discussed 
here for the first time.  
 
The hydrodistilled essential oil (0.7% w/w or 7 g/1000 g dry 
weight) component was analysed using GC and GC-MS which 
detected 53 constituent peaks of the chromatographable fraction of 
the total injected oil (Table 1). Of these, 44 compounds were 
identified with (3R,6R)-linalool oxide acetate (75.8%) as the  major 
constituent, followed by 6-ethenyldihydro-2,2,6-trimethyl-2H-
pyran-3(4H)-one (4.6%), β-farnesene (2.9%), epoxylinalol (2.8%), 
germacrene D (1.4%), bisabolol oxide A (1.2%), chamazulene 
(1%), (E)-2-(2,4-hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene 
(1%), and (Z)-2-(2,4-hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-
ene (1%).  
 
The percent contents of the EO were determined on the basis of 
their FID responses on GC. All the identified compounds are 
presented in Table 1. 
 
Table 1: EO constituents of aerial parts of Ajania nubigena. 
Compound name KI† % oil 
α-pinine 934 0.1 
β-citrollene 947 0.1 
1-methylpentyl hydroperoxide 949 0.1 
benzaldehyde 957 0.1 
cis-linalool oxide 1090 0.3 
 
 
2    
β-linalool 1098 0.2 
6-ethenyldihydro-2,2,6-trimethyl-2H-pyran-3(4H)-one   1108 4.6 
L-pinocarveol 1141 0.1 
L-camphor 1147 t 
pinocarvone 1164 0.1 
(-)-borneol 1168 0.3 
epoxylinalol 1175 2.8 
homoveratrole 1240 0.2 
(3R,6R)-linalool oxide acetate 1291 75.8 
eugenol 1359 0.1 
α-copaene 1381 0.5 
aromadendrene 1426 0.2 
β-farnesene 1459 2.9 
unidentified 1463 0.2 
5-ketobornyl acetate 1470 0.1 
seychellene 1473 0.1 
germacrene D 1482 1.4 
patchoulene 1493 0.1 
unidentified 1500 0.4 
α-muurolene 1506 0.1 
α-bisabolene 1513 0.1 
epiglobulol 1522 0.4 
unidentified 1529 0.4 
(Z)-α-bisabolene epoxide* 1560 0.1 
sapathulenol 1585 0.3 
caryophyllene oxide 1592 0.1 
isoaromadendrene epoxide 1595 0.3 
unidentified 1600 0.1 
unidentified  1613 0.2 
6-hexadecen-4-yne 1619 0.2 
unidentified 1636 t 
cubenol 1636 0.1 





eudesm-4(14)-en-11-ol 1659 0.5 
τ-cadinol  1662 0.3 










chamazulene  1720 1.0 
bisabolol oxide A  1754 1.2 
unidentified 1766 0.1 
benzyl benzoate  1776 0.2 
1-octadecyne* 1844 0.3 
(E)-2-(2,4-hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene 1887 1.0 
(Z)-2-(2,4-hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene 1931 1.0 
1-phenylbicyclo[3.3.1]nonan-9-one*  1960 0.1 
 
Note: components larger than 1% are highlighted in bold face; t = trace components 
below 0.04% of oil; † = Kovats indices;  
* = tentatively identified.  
 
With reference to the Indian varieties reported, no bornyl acetate or 
(-)-cis-chrysanthenol were detected in our study thereby confirming 
that the major constituent of this Bhutanese variety of A. nubigena 
was chemotype II. Notably, chamazulene, with a characteristic blue 
color, was detected and isolated here as a new sub-chemotype for 
the first time from this species. 
 
The repeated purification of the EO and the crude MeOH extract 
using column chromatography and preparative TLC resulted in the 
isolation of eight major compounds (Fig. 1).  
 
While (3R,6R)-linalool oxide acetate (1) [12], chamazulene (2) [13], 
(E)-2-(2,4-hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene (3) [12], 
and (Z)-2-(2,4-hexadinylidene)-1,6-dioxaspiro[4,4]non-3-ene (4) 
[12] were isolated from the EO component, 1-(4-hydroxy- 
phenyl)propan-1-one (5) [14], oxyanin B (6) [15], luteolin (7) [16-
17] and the luteolin-7-O-β-D-glucopyranoside (8) [18] were 
obtained from the crude MeOH extract component. They were 
characterized from their MS, 1D and 2D-NMR spectroscopic data 
and comparisons made with the data reported. Compound 6 lacked 





Figure 1: The structures of isolated compounds 1-8. 
 
 
The EO and the eight isolated compounds 1−8 were investigated for 
their antiplasmodial, antimicrobial and cytotoxic activities. These 
results, along with the positive controls and the bioassay data on the 
crude MeOH, hexane, CH2Cl2 and CHCl3 extracts, which we 
previously reported [6], are shown in Table 2. The EO exhibited 
moderate antiplasmodial activities against Plasmodium falciparum 
strains: TM4/8.2 (a wild type chloroquine and antifolate sensitive 
strain) and K1CB1 (multidrug resistant strain). The antimalarial 
activities of the crude extracts that we previously reported [6] were 
almost seven fold more potent than that of EO. The EO also 
displayed strong antibacterial activity against Bacillus subtilis (in 
comparison to that of the standard, amoxicillin) and moderate 
antifungal activity against Candida albicans with the minimum 
inhibition zones (MIZ) of 13 mm and 11 mm, respectively. 
Interestingly, while the (E)-spiroether (3), isolated from the EO, 
displayed only moderate antiplasmodial activities, its isomeric form 
(Z)-spiroether (4) demonstrated only selective antimicrobial 
activities (Table 2).  
 
Among the four flavonoid compounds tested for various 
bioactivities (Table 2), compound 7 showed broad spectrum 
activities against all subset of test organisms. It exhibited good 
antimalarial activities against both the TM4/8.2 and K1CB1 strains 
of P. falciparum with IC50 values of 6.2±1 µg/mL and 6.2±1 µg/mL, 
respectively. It also demonstrated the highest cytoxicity against the 
Vero and human oral carcinoma KB cells with the IC50 value of 
14.5±7 µg/mL and 14.3±1 µg/mL, respectively.  
Table 2: Bioactivities of the crude extractsa, EO and the pure compounds 1−8 isolated from A. nubegina 
 
*MIZ: minimum inhibition zone with a well diameter of 4 mm. Nt: Not tested. −: Not active. a results reproduced from earlier report [12].  b Reference drugs for antiplasmodial 
activity. c Reference drugs for cytotoxicity and anticancer activities. d Reference drugs for antibacterial activity. e Reference drug for antifungal activity.        
 
 
Compound 7 showed inhibitory activities against all Gram-positive 
bacteria (B. subtilis, Staphylococcus aureus, methicillin resistant S. 
aureus (MRSA), S. epidermidis) and fungi (C. albicans) with MIZ 
values in the range of 5-10 mm (Table 2). These inhibitions were 
significant when compared to that of the positive controls. 
However, when the MIC values of this compound (including other 
test samples) were determined, the best MIC-based activity 
observed was 125 µg/mL against MRSA and S. epidermidis. While 
the broad spectrum bioactivity of compound 7 implied that it could 
be a general toxin, the literature confirmed that it was in fact a 
common natural antioxidant flavone which had already been 
extensively studied and was shown to have a better safety profile 
[19]. Preclinical studies have shown that luetolin (7) possesses a 
variety of bioactivities, including pro-oxidant, anti-inflammatory 
and antimicrobial [20]. Further, its ability to inhibit angiogenesis, to 
induce apoptosis, to prevent carcigenosis in animal models, to 
reduce tumor growth in vivo and to sensitize tumor cells to the 
cytotoxic effects of some anticancer drugs suggests that this 
flavonoid has cancer chemopreventative and chemotherapeutic 
potential [20]. Luetolin (7) has been previously studied and found 
effective against leukemia, melanoma and carconomas of the 
pancreas, ovary, brain, kidney, lung, colon and stomach [21]. Our 
study demonstrated the cytoxicity of this compound against human 
oral carcinoma KB cells. 
 
In contrast to compound 7, its glycosylated analog 8 showed more 
selectivity, being only active against a subset of the targets (Table 
2). Compound 8 exhibited the best (among test samples) and highly 
significant antimalarial activities with IC50 values of 2.8±1 µg/mL 
and 2.0±1 µg/mL against TM4/8.2 and K1CB1 strains, respectively. 
Its antimalarial activity is three fold more active than the parent 
crude extracts (Table 2). Compound 8 also exhibited mild 
cytotoxicty against the Vero cells with an IC50 value of 33.2±4 
µg/mL but with no cytotoxicity to the human oral carcinoma KB 
cells. An earlier study showed that this compound was not toxic to 
RAW264.7 cells and also demonstrated that its aglycone luteolin (7) 
was more toxic than the glycosylated form [22]. The fact that 
cytotoxicity of compound 8 was lower than its aglycone 7, suggests 
that glycosylation reduces cytotoxicity. This has been substantiated 
by the fact that it is closely related derivatives, kaempferol and 
quercetin, had higher toxicities compared to their glycosides [23]. 
Higher lipophilicity facilitates greater penetration into the lipid 
membrane of organisms and therefore greater cytotoxicity which 
explains the higher toxicity of compound 7 compared to its 
glycosylated compound 8. This compound 8, with significant 
antimalarial activities and lesser cytotoxicity, would serve as a 
potential lead for developing an analogue with a better antimalarial 
therapeutic index.  
 
In conclusion, our study found that the Bhutanese variety of A. 
nubigena contained: a) an essential oil (0.7% w/w) with (3R,6R)-
linalool oxide acetate as the  major constituent (75.8%) (chemotype 
II) and chamazulene as the new sub-chemotype; b) luteolin (7) as 
the major marker compound of the crude MeOH extract which 
exhibited a broad range of moderate antiplasmodial, cytoxicity and 
antimicrobial activities; and c) compound 8 which showed 
significant in vitro antiplasmodial activity with mild cytotoxicity 
which was identified as a potential antimalarial scaffold. The in 
vitro antimicrobial and cytotoxicity activities of the crude extracts, 
EO and compounds 1, 3-4, and 7- 8 were supportive of the use of 
this plant in BTM as a vulnerary, expectorant and for treating 
abcess, swelling and tumors [6].  
 
Experimental 
Plant material: A. nubegina, is a perennial flowering herb of 30 cm 
tall with slender fibrous roots and yellow flowers. It grows in alpine 
mountain rocky slopes and sandy grounds of Bhutan at an elevation 
range of 3600–4800 meters above sea level [24]. The aerial parts of 
wild A. nubegina were collected from Lingzhi in Bhutan in August 
2009. The collected plant material was air-dried and a herbarium 
specimen with voucher number 73 was deposited at the herbarium 
of the PRU, Thimphu, Bhutan. 
 
Extraction of EO and crude methanol extract: The pale green 
pleasantly aromatic EO (7 mL) was obtained by hydro-distillation 
(temperature at 60 °C) of 1 kg of dried plant material using a 
Clevenger apparatus for three hours. The EO collected was dried 
over anhydrous magnesium sulphate. Alternatively, air-dried plant 
material (2 kg) was chopped into small pieces and was repeatedly 
extracted with methanol (AR/HPLC grade, 5 × 3 L over 48 h). The 
Antiplasmodial (IC50 in µg/mL) Cytotoxicity (IC50 in µg/mL) Antibacterial (MIZ* in mm)  Antifungal (MIZ* in mm) 
Samples TM4/8.2   K1CB1 VERO KB  S. aureus B. subtilis S. epidermidis MRSA   C. albicans 
MeOH extracta 9.8±1 8.7±1 >10 >10 5 5 – 6.5   – 
Hexane extracta >12.5 6.2±3 >10 >10 5 5 – 5.5   – 
CH2Cl2 extract
a >12.5 9.5±1 >10 >10 – 5 – 5.5   – 
CHCl3 extract
a 20.0±4 18.7±1 >25 >25 – 5.5 – –   – 
EO 66.1±2 70.6±5 >100 >100 – 13 – –   11 
1 >100 >100 >100 >100 – 8 – –   5 
2 >20 >20 >20 >20 Nt Nt Nt Nt   Nt 
3 7.3±2 8.8±1 >10 >10 – 7 – –   5 
4 >20 >20 >20 >20 – 11 8 –   5 
5 >10 >10 >10 >10 Nt Nt Nt Nt   Nt 
6 >20 >20 >20 >20 – – – –   – 
7 6.2±1 6.2±1 14.5±2 14.3±2 8 7 10 10   5 
8 2.8±1 2.0±1 33.2±4 >45 – 6 – –   – 
Chloroquineb 0.009 0.08           
Cycloguanilb 0.009 0.8           
Pyrimethamineb 0.02 7.7           
Ellipticinec   0.09         
Doxorubicinc    0.5        
Amoxycillind     34 10 20     
Vancomycind        15    
Amphotericin Be                         20 
4    
extract was filtered and then concentrated using a rotary evaporator 
to afford the crude methanol extract (58.22 g).   
 
Analysis of EO using GC and GC-MS: The EO was analysed for its 
chemical constituents using GC and GC-MS systems. The GC 
analysis was performed on a Shimadzu GC-2010 Plus gas 
chromatograph. Hydrogen was used as carrier gas (1.5 mL/min at 
40 °C in a constant total flow mode) and the separation was 
achieved using a Restek fused silica capillary column (Rxi-5MS: 30 
m × 0.25 mm i.d., 0.25 µm film thickness). Injector and detector 
temperature were set at 260 °C and 300 °C, respectively. The 
starting oven temperature was programmed at 40 °C with an 
increasing temperature of 6 °C/min until it reached to 290 °C. 
Kovats retention indices (KI) were obtained by GC-FID analysis of 
an aliquot of the EO spiked with an n-alkane mixture (C7 to C30). 
The GC-MS analysis was performed using Shimadzu QP5050A 
GC-MS system (electron impact (EI) mode at 70 eV). The column 
and the GC-MS chromatographic conditions were same as that for 
GC but He was used as carrier gas. The EO constituents were 
identified by comparing mass spectra with NIST and NISTREP 
mass spectra library of GC-MS data system and further confirmed 
by comparing their Kovats indices (KI) with those reported [8, 11-
12, 25]. About 53 component peaks were detected and 44 of them 
have been identified through MS library matching and KI 
comparison techniques. 
 
Isolation of compounds from EO and methanol extract: A rotary 
evaporator was used for solvent evaporation under reduced pressure 
at 35 °C – 50 °C. Flash column chromatography packed with Merck 
Kieselgel 60 PF254 and the pre-coated silica plates (0.2 mm silica 
thickness, Merck) were used for separation and purification of 
compounds. UV light (short wavelength of 254 nm, long 
wavelength of 366 nm) and ceric ammonium molybdate (CAM) 
were used for visualization and detection of the compounds on TLC 
plates. Micromass Waters Platform LCZ (single quadrupole, MeOH 
as solvent) was used for obtaining the LR-ESI-MS. Shimadzu 
GCMS-QP-5050 was used for recording the LR-EI-MS by the 
direct insertion technique (at 70 eV). Micromass Waters Q-ToF 
Ultima (quadrupole time-of-flight) mass spectrometer was used for 
acquiring HR-ESI-MS. A 500 MHz Varian Unity Inova, 500 MHz 
Varian Premium Shield (VNMRS PS 54), and 300 MHz Varian 
Mercury spectrometer were used for obtaining the 1D and 2D-NMR 
spectra using deuterated solvents depending upon the solubility of 
compounds. The known compounds were identified through MS 
library matching techniques (NIST and NISTREP mass spectra 
library) and then confirmed through comparison of their optical 
rotation, MS and NMR spectra with those reported in the relevant 
literature. 
 
The repeated purification of the EO (5.6 ml) using column 
chromatography, preparative TLC and reverse phase (RP) silica-
coated preparative TLC resulted in the isolation of four compounds 
as: (3R,6R)-linalool oxide acetate (1), chamazulene (2), (E)-2-(2,4-
hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene (3) and (Z)-2-(2,4-
hexadinylidene)-1,6-dioxaspiro[4,4]non-3-ene (4).  
Subsequently, the MeOH extract (70.12 g) was fractionated with 
hexane followed by ethyl acetate. Two fractionated extracts were 
concentrated resulting into hexane extract (28 g) and the ethyl 
acetate extract (12.5 g). The silica gel column chromatography 
seperation yielded 17 fractions (AN-1 to AN-17). Seperation of 
fraction AN-4 using silica-coated preparative TLC plates with a 
mobile phase of H2O (20%):MeOH (80%) yielded 1-(4-
hydroxyphenyl)propan-1-one (5) and oxyanin B (6). Fractional 
crystallization of AN-8 with MeOH/CHCl3 yielded crystal 
compound luteolin (7). Purification of fraction AN-14 using RP 
silica gel column chromatography with an isocratic mobile phase of 
100% MeOH furnished luteolin-7-O-β-D-glucopyranoside (8).   
 
Oxyanin B (6) 
1H NMR (500 MHz, DMSO-d6): 6.52 (1H, s, H-8), 6.94 (1H, d, J =  
8.5 Hz, H-3′), 7.54 (1H, d, J = 8.5 Hz, H-2′), 7.61 (1H, s, H-6′), 
3.49 (1H, bs, C(6)-OH), 12.73 (1H, bs, C(5)-OH), 3.73 (3H, s, C(7)-
OMe), 3.77 (3H, s, C(3)-OMe), 3.83 (3H, s, C(4′)-OMe). 
13C NMR (125 MHz, DMSO-d6): 55.7 (C(4′)-OMe), 59.7 (C(3)-
OMe), 59.8 (C(7)-OMe), 94.2 (C-8), 104.3 (C-10), 112.0 (C-6′), 
115.6 (C-3′), 120.8 (C-1′), 122.1 (C-2′), 131.3 (C-7), 137.3 (C-3), 
147.4 (C-4′), 149.7 (C-5′), 151.7 (C-6), 152.2 (C-5), 155.2 (C-2), 
177.9 (C-4).  
 
Bioassays: The EO and compounds 1-8 were tested in vitro for their 
antiplasmodial, antimicrobial and the cytotoxicity activities using 
the standard test protocols as described by us previously [12].  
 
For antimalarial testing a multidrug resistant K1CB1 strain and a 
wild type chloroquine and antifolate sensitive TM4/8.2 strain of 
Plasmodium falciparum were used in the Microdilution 
Radioisotope Technique. Chloroquine (Sigma), pyrimethamine 
(Sigma) and cycloguanil were used as reference drugs for both the 
plasmodial strains.  
 
For the antimicrobial assay, the test organisms including 
Escherichia coli (ATCC 25922), Bacillus subtilis (ATCC 6633), 
Staphylococcus aureus (ATCC 6538), methicillin resistant S. 
aureus (MRSA), (DMST 20651), Staphylococcus epidermidis 
(ATCC 12228), Vibrio cholerae (DMST 2873) and Candida 
albicans (ATCC 10231) were used. Amphotericin B (Sigma-
Aldrich, USA), vancomycin (Edicin, Slovenia) and amoxicillin 
(GPO, Thailand) were used as a reference drugs. 
 
For the cytotoxicity assay, normal vero cells from kidney of African 
green monkey, Cecopithecus aethiops and the human oral 
carcinoma KB cells were used. Ellipticine and doxorubicin were 
used as reference drugs. 
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